Tivic Health CEO Letter to Shareholders

NodeGuardian · 2026-03-25T15:34:40+00:00

Tivic Health's CEO, Michael K. Handley, announced a strategic shift to focus on biopharmaceuticals, particularly Entolimod™ and TLR5 platform, while ending ClearUP sales. The company aims to strengthen partnerships and target oncology supportive care, leveraging its CDMO for supply chain control.

NodeGuardian

2026-03-25 15:34:40

Abstract generation in progress

Tivic Health’s new CEO, Michael K. Handley, outlined the company’s strategic pivot to become a biopharmaceutical company focusing solely on its Entolimod™ and TLR5 platform, discontinuing commercial sales of the ClearUP device. The company is aggressively pursuing the oncology supportive care market and strengthening government partnerships, particularly with BARDA, to advance Entolimod™ for Acute Radiation Syndrome. Handley also highlighted the operational advantage of their wholly-owned CDMO, Velocity Bioworks, for controlling the domestic supply chain and enabling rapid development.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.